Lack of Increased Hepatotoxicity in HIV-infected Pregnant Women Receiving Nevirapine Compared with Other Antiretrovirals

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2009 Nov 21

PMID 19926957

Citations 10

Authors

David W Ouyang

Susan B Brogly

Ming Lu

David E Shapiro

Ronald C Hershow

Audrey L French

Robert M Leighty

Bruce Thompson

Ruth E Tuomala

Affiliations

Soon will be listed here.

Abstract

Objective: To estimate whether HIV-infected pregnant women were at an increased risk of hepatotoxicity when taking nevirapine (NVP)-containing regimens compared with HIV-infected pregnant women taking antiretroviral therapy (ART) not containing NVP.

Methods: This analysis included HIV-infected pregnant women on ART from two multicenter, prospective cohorts: the Women and Infants Transmission Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials protocol P1025. Multivariate Cox proportional hazards regression models were used to investigate the association between NVP use and hepatotoxicity. NVP use was dichotomized as use or no use and further categorized according to ART exposure history. We investigated two outcomes: any liver enzyme elevation (LEE) (grade 1-4) and severe LEE (grade 3-4).

Results: A total of 1229 women with ART use during pregnancy were studied, 218 (17.7%) of whom received NVP. Among the women receiving NVP, 137 (62.8%) were NVP naive. Twenty-nine women (13.3%) who received NVP developed any LEE and one (0.5%) developed severe LEE. Of the 1011 women on non-NVP regimens, 145 (14.3%) developed any LEE and 14 (1.4%) developed severe LEE. There were no maternal deaths. In univariate models, LEE was not significantly associated with CD4 cell count above 250 cells/mul or NVP use. In adjusted multivariate models, no significant increased risk of LEE (any or severe) in women taking NVP was detected as compared to those taking other ART regardless of prior exposure history.

Conclusion: We did not observe an increased risk of hepatotoxicity among HIV-infected pregnant women on NVP versus other ART, including women who were ART naive.

Citing Articles

The Impact of Antiretroviral Therapy on Liver Function Among Pregnant Women Living with HIV in Co-Existence with and Without Pre-Eclampsia.

Strauss K, Phoswa W, Mokgalaboni K Viruses. 2025; 17(1).

PMID: 39861817 PMC: 11768528. DOI: 10.3390/v17010028.

Liver injury associated with drug intake during pregnancy.

Kamath P, Kamath A, Ullal S World J Hepatol. 2021; 13(7):747-762.

PMID: 34367496 PMC: 8326163. DOI: 10.4254/wjh.v13.i7.747.

Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?.

Fairlie L, Waitt C, Lockman S, Moorhouse M, Abrams E, Clayden P J Int AIDS Soc. 2019; 22(9):e25372.

PMID: 31529598 PMC: 6747006. DOI: 10.1002/jia2.25372.

Safety of protease inhibitors in HIV-infected pregnant women.

Chougrani I, Luton D, Matheron S, Mandelbrot L, Azria E HIV AIDS (Auckl). 2013; 5:253-62.

PMID: 24101883 PMC: 3790874. DOI: 10.2147/HIV.S33058.

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.

Usach I, Melis V, Peris J J Int AIDS Soc. 2013; 16:1-14.

PMID: 24008177 PMC: 3764307. DOI: 10.7448/IAS.16.1.18567.

References

Sulkowski M, Thomas D, Chaisson R, Moore R . Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000; 283(1):74-80. DOI: 10.1001/jama.283.1.74. View

Tuomala R, Watts D, Li D, Vajaranant M, Pitt J, Hammill H . Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005; 38(4):449-73. DOI: 10.1097/01.qai.0000139398.38236.4d. View

Brogly S, Read J, Shapiro D, Stek A, Tuomala R . Participation of HIV-infected pregnant women in research in the United States. AIDS Res Hum Retroviruses. 2007; 23(1):51-3. DOI: 10.1089/aid.2006.0045. View

Miller W, Aberg J, van der Horst C, Hamrick Jr H, Powderly W, Mundy L . Sex differences in nevirapine rash. Clin Infect Dis. 2000; 32(1):124-9. DOI: 10.1086/317536. View

Joy S, Poi M, Hughes L, Brady M, Koletar S, Para M . Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol. 2005; 106(5 Pt 1):1032-8. DOI: 10.1097/01.AOG.0000180182.00072.e3. View

Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangclaviraj S . Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med. 2007; 8(6):357-66. DOI: 10.1111/j.1468-1293.2007.00477.x. View

Sanne I, Mommeja-Marin H, Hinkle J, Bartlett J, Lederman M, Maartens G . Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005; 191(6):825-9. DOI: 10.1086/428093. View

Stern J, Robinson P, Love J, Lanes S, Imperiale M, Mayers D . A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003; 34 Suppl 1:S21-33. DOI: 10.1097/00126334-200309011-00005. View

Hitti J, Frenkel L, Stek A, Nachman S, Baker D, Gonzalez-Garcia A . Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004; 36(3):772-6. DOI: 10.1097/00126334-200407010-00002. View

10.

Lyons F, Hopkins S, Kelleher B, McGeary A, Sheehan G, Geoghegan J . Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med. 2006; 7(4):255-60. DOI: 10.1111/j.1468-1293.2006.00369.x. View

11.

Joao E, Calvet G, Menezes J, DIppolito M, Cruz M, Salgado L . Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol. 2006; 194(1):199-202. DOI: 10.1016/j.ajog.2005.05.015. View

12.

Natarajan U, Pym A, McDonald C, Velisetty P, Edwards S, Hay P . Safety of nevirapine in pregnancy. HIV Med. 2007; 8(1):64-9. DOI: 10.1111/j.1468-1293.2007.00433.x. View

13.

Martin A, Nolan D, James I, Cameron P, Keller J, Moore C . Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005; 19(1):97-9. DOI: 10.1097/00002030-200501030-00014. View

14.

Marazzi M, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A . Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med. 2006; 7(5):338-44. DOI: 10.1111/j.1468-1293.2006.00386.x. View

15.

Chng C, Morgan M, Hainsworth I, Kingham J . Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut. 2002; 51(6):876-80. PMC: 1773454. DOI: 10.1136/gut.51.6.876. View

16.

Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N . Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr. 2007; 44(4):371-6. DOI: 10.1097/QAI.0b013e318032bbee. View

17.

Wit F, Weverling G, Weel J, Jurriaans S, Lange J . Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002; 186(1):23-31. DOI: 10.1086/341084. View